Literature DB >> 11953727

Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide.

Paul H Lipkin1, Dennis Davidson, Lynn Spivak, Richard Straube, Jared Rhines, C T Chang.   

Abstract

OBJECTIVE: To determine the medical and neurodevelopmental outcome of children with moderately severe persistent pulmonary hypertension of the newborn (PPHN) treated with or without inhaled nitric oxide (I-NO). STUDY
DESIGN: Term infants with PPHN and a baseline oxygenation index of 24 +/- 9 at study entry were randomly assigned to early treatment with placebo or initial doses of I-NO (5, 20, and 80 ppm). Outcome was measured at approximately 1 year by frequency of hospitalization, growth, and neurodevelopmental and audiologic evaluation.
RESULTS: Of 155 children enrolled, 144 survived, and there was follow-up for 133. No significant differences between the placebo and the I-NO groups were seen in any long-term outcome. Rehospitalization occurred in 22%, and growth did not differ. The composite neurodevelopment and audiologic outcome showed impairment in 46% of the infants. There were major neurologic abnormalities in 13%, cognitive delays in 30%, and hearing loss in 19% of the infants.
CONCLUSIONS: Moderately severe PPHN at 24 hours after birth is associated with high rates of rehospitalization and disability at 1 year. Adverse outcomes were the same in I-NO and control groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953727     DOI: 10.1067/mpd.2002.122730

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Lung Rest During Extracorporeal Membrane Oxygenation for Neonatal Respiratory Failure-Practice Variations and Outcomes.

Authors:  Deepthi Alapati; Zubair H Aghai; Md Jobayer Hossain; Daniel R Dirnberger; Mark T Ogino; Thomas H Shaffer
Journal:  Pediatr Crit Care Med       Date:  2017-07       Impact factor: 3.624

2.  Inhaled nitric oxide use in newborns.

Authors:  Abraham Peliowski
Journal:  Paediatr Child Health       Date:  2012-02       Impact factor: 2.253

3.  Management of Supplemental Oxygen for Infants with Persistent Pulmonary Hypertension of Newborn: A Survey.

Authors:  Deepthi Alapati; Romal Jassar; Thomas H Shaffer
Journal:  Am J Perinatol       Date:  2016-08-04       Impact factor: 1.862

4.  Decreased OLA1 (Obg-Like ATPase-1) Expression Drives Ubiquitin-Proteasome Pathways to Downregulate Mitochondrial SOD2 (Superoxide Dismutase) in Persistent Pulmonary Hypertension of the Newborn.

Authors:  Adam Schultz; Olubunmi A Olorundami; Ru-Jeng Teng; Jason Jarzembowski; Zheng-Zheng Shi; Suresh N Kumar; Kirkwood Pritchard; Girija G Konduri; Adeleye J Afolayan
Journal:  Hypertension       Date:  2019-09-03       Impact factor: 10.190

Review 5.  Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

Authors:  Enrique M Ostrea; Esterlita T Villanueva-Uy; Girija Natarajan; Herbert G Uy
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Persistent Pulmonary Hypertension of the Newborn.

Authors:  Satyan Lakshminrusimha; Martin Keszler
Journal:  Neoreviews       Date:  2015-12

Review 7.  Nitric oxide for respiratory failure in infants born at or near term.

Authors:  Keith J Barrington; Neil Finer; Thomas Pennaforte; Gabriel Altit
Journal:  Cochrane Database Syst Rev       Date:  2017-01-05

8.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

Review 9.  Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.

Authors:  G Ganesh Konduri; U Olivia Kim
Journal:  Pediatr Clin North Am       Date:  2009-06       Impact factor: 3.278

Review 10.  The fetal circulation, pathophysiology of hypoxemic respiratory failure and pulmonary hypertension in neonates, and the role of oxygen therapy.

Authors:  S Lakshminrusimha; O D Saugstad
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.